Kornimate/medical-research-clean huggingface dataset:
three-dimensional breathing patterns in postpartum stress urinary incontinence

Conditions: Stress Urinary Incontinence (SUI)

Summary: \*\*clinical trial\*\* the purpose of this clinical trial is to determine whether three-dimensional breathing training is effective in treating postpartum stress urinary incontinence (ppsui). the main question it aims to answer is: can three-dimensional breathing training improve or treat postpartum stress urinary incontinence? participants will: * receive one-on-one verbal health education covering the causes and risk factors of ppsui, benefits and precautions of pelvic floor exercises and breathing, and implementation methods. * engage in app-based three-dimensional breathing training and learn to use a biofeedback pressure device at home for proper and effective training. they will also be guided to log their daily training, manually inputting data such as duration and frequency. a virtual assistant will provide real-time feedback based on this data, including encouragement and adjustments to training intensity.

user experience quality control 1. establish a dedicated technical team for system testing and quality control to ensure stable operation of the app and accurate data. 2. regularly update and optimize the virtual characters to guarantee the best user experience. data security and privacy protection 1. ensure that all user data is encrypted to protect user privacy and data security. 2. comply with relevant regulations and standards to ensure the lawful use and protection of user data.

Eligibility criteria:
inclusion criteria: 1. age: 20-35 years 2. postpartum: 42 to 49 days 3. diagnosed with pure postpartum stress urinary incontinence (ppsui) by an experienced obstetrician/gynecologist during the first postpartum check-up, according to the international continence society (ics) standards. exclusion criteria: 1. bmi \&gt; 30 kg/m² 2. cesarean section 3. multiparous women 4. pathological conditions or deformities of the spine 5. history of lumbopelvic surgery 6. urogenital prolapse of grade 2 or higher 7. professional athletes 8. severe cardiopulmonary conditions during pregnancy or postpartum 9. neurological diseases or cognitive impairments 10. individuals unable to meet study requirements

Keywords: three-dimensional breathing postpartum stress urinary incontinence elvic diaphragm dynamics pelvic floor exercises
sunlight exposures effect on serum vitamin d levels

Conditions: Vitamin D Deficiency

Summary: when people eat a meal, some, but not all of the calcium in that meal is absorbed, that is, moved into the bloodstream. when the skin is exposed to sunlight during summer months, vitamin d is made there and then modified into more active forms by the liver and kidneys. these more active forms of vitamin d improve calcium absorption. many adults living in the u.s. have little or no sun exposure and are low in vitamin d. we know that specific wavelengths of sunlight called ultraviolet-b cause vitamin d to be made in the skin.

at the beginning of the study we will measure your height, weight, skin color, and draw blood to measure your blood levels of vitamin d and 25-hydroxyvitamin d. each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).we will draw blood for vitamin d and 25-hydroxyvitamin d on days 1,2,3,5, and 7 after sunlight exposure. there will be six blood draws for a total of 102 cc of blood drawn (about 3 ½ teaspoons drawn each time).

Eligibility criteria:
inclusion criteria: * healthy males or females ages19-50 with "light" skin (self-assessed as fitzpatrick skin type i-iii) with minimal sun exposure and exogenous sources of vitamin d. exclusion criteria: * less than 16 oz milk per day, less than 10 hours of sun per week, no vitamin d supplements, no anticonvulsants, no barbiturates, no steroids, no meds that increase photosensitivity, no granulomatous disease, no liver or kidney disease, no history of skin cancer, and bmi less than 30.

Keywords: sunlight uvb vitamin d
immune monitoring in sensitized patients at risk of rejection

Conditions: Kidney Failure

Summary: the purpose of this study is to test the effect of anti-rejection medications on your immune system

recipients of deceased or living donor transplants with calculated percent reactive antibody (cpra) of 50% or greater at university of california, san francisco (ucsf) will be enrolled in the trial. samples for kidney solid organ response test (ksort) will be obtained pre-transplant (and immunosuppression) and post-transplant (see table 1). urine will be obtained at the same true intervals including pre-transplant in patients who still produce urine to correlate with graft rejection, inflammation and ksort. a piece (minimum 1/3 core) of the protocol or for cause biopsy tissue will be saved in ribonucleic acids (rna) later for gene expression analysis as a correlate of graft inflammation with the biopsy, ksort and urine. in addition, samples will be when patients are undergoing cause kidney biopsy, prior to treatment intensification and procedure. patient's who are treated for rejection, will have additional samples obtained 2-4 weeks after treatment of rejection and at the time of any followup biopsy for monitoring resolution of biopsy confirmed acute rejection.

Eligibility criteria:
inclusion criteria: 1. 18 years or older able to consent 2. no history of hiv, hepatitis c and active hepatitis b infection 3. cpra ≥ 50% exclusion criteria: 1. patients on coumadin 2. human leukocyte antigen (hla) identical donor recipient patients

Keywords: kidney transplant recipient
sore throat in primary care - a comparison of phenoxymethylpenicillin and no antibiotic treatment

Conditions: Sore Throat; Tonsillitis

Summary: sore throat is the second most common cause of antibiotic prescribing in primary care in sweden. guidelines for sore throat focus on identifying people with sore throat where there are 3 and 4 specified criteria and where near patient tests identify group a streptococci (gas). in these cases, phenoxymethylpenicillin is recommended. studies that have identified microorganisms in sore throat show that there are other bacteria and viruses than gas, that give similar symptoms and that sometimes no microorganism is trapped despite pronounced symptoms. in recent years, a bacterium f. necrophorum has been identified, which is found in increased incidence of sore throat, but it is also found in healthy individuals. in clinical practice, many patients are treated with penicillin even if gas is not captured. this may be because the doctor perceives the patient as sick or because other bacteria are not caught with a near patient test which causes the doctor to treat anyway. the specific aims are to in patients with gas-negative sore throat and 3 and 4 criteria, aged 15 years and older in primary care, study whether phenoxymethylpenicillin treatment shortens the duration of the disease, reduces the symptom intensity and sickness absence, and investigates the importance of other microorganisms than gas in sore throat. the study is a randomized controlled trial in which patients with sore throat are randomized to phenoxymethylpenicillin 3 times daily for 10 days or to no antibiotic therapy. there will also be and a reference group with severe (centor score 3-4), gas-positive acute tonsillitis. blood samples for inflammatory and immunological response to infections are taken. throat samples for culture of f. necrophorum and streptococcal groups c and g, as well as polymerase chain reaction (pcr) analysis for bacteria and viruses are also taken at inclusion and at follow-up. the outcome will be followed in a patient diary for 10 days and at a return visit after 18-24 days where the clinical outcome is asked for and where the blood- and throat samples are repeated. follow-up will also takes place via e-mail after 1 and 3 months.


Eligibility criteria:
inclusion criteria: ' centor score 3-4: absence of cough, anamnestic fever (temperature \>38.5°c), tender cervical lymphadenitis, and tonsillar exudates (one or both tonsils) * duration of symptoms \< 8 days * rapid antigen detection test for gas taken and negative * willing and able to give informed consent. subjects under 18 years of age must in addition have the consent from both parents/caretakers exclusion criteria: * ongoing antibiotic treatment * known or suspected allergies to phenoxymethylpenicillin * suspicion of peritonsillar abscess or indication for admittance.

Keywords: sore throat tonsillitis randomized controlled trial primary care phenoxymethylpenicillin
luminopia one pilot study

Conditions: Amblyopia

Summary: a single-arm, multi-center, open-label pilot study to evaluate the feasibility, safety, and efficacy of the luminopia one digital therapeutic in improving visual acuity in a pediatric amblyopia population.


Eligibility criteria:
major eligibility criteria: * age 4 to \<8 years (phase 1) or age 4 to \<13 years (phase 2) * monocular amblyopia associated with anisometropia, strabismus or both combined * amblyopic eye best-corrected visual acuity (bcva) 20/40 to 20/200 inclusive (0.3-1.0 logmar) * fellow eye bcva 20/25 or better (phase 1) or 20/32 or better (phase 2) * interocular bcva difference ≥3 lines (≥0.3 logmar) * visual acuity stability in current refractive correction (phase 2) * corrected distance heterotropia ≤5 prism diopters on simultaneous prism and cover test (spct)
lidocaine versus magnesium sulphate in management of myofascial pain dysfunction syndrome

Conditions: Myofascial Pain Dysfunction Syndrome

Summary: the goal of this clinical trial is to investigate the effectiveness of magnesium sulphate in the management of myofascial pain dysfunction syndrome in comparison to lidocaine and saline. a total of 75 patients suffering from myofascial pain dysfunction syndrome will be assigned into one of three groups, each with 25 patients. group a: (saline) includes patients enrolled for saline injection into the trigger points. group b: (magnesium sulphate) includes patients enrolled for magnesium sulphate injection into the trigger points. group c: (lidocaine) includes patients who will be enrolled for lidocaine injection into the trigger points the primary outcome that will be investigated is (pain with a visual analogue score), and secondary outcomes will be (maximum mouth opening between edges of upper and lower incisors with millimeters, electrical activity with electromyography, and quality of life assessed using the oral health impact profile questionnaire) the outcomes will be assessed pre-injection, 1month after injection, 3months after injection, and 6 months after injection


Eligibility criteria:
inclusion criteria: * age limitations: participants must be between 18 and 55 years old. * chronic pain diagnosis: individuals must have a diagnosis of chronic myofascial pain dysfunction syndrome (mpds) affecting the face muscles, neck, shoulder, or upper back for a duration exceeding three months. * trigger point recognition: patients must show awareness of their pain when pressure is applied to identified myofascial trigger points, in accordance with established diagnostic guidelines. * consent to participate: willingness to provide informed consent and engage in all aspects of the study. exclusion criteria: * previous treatments: a history of receiving dry needling or pulsed radiofrequency therapy, or currently participating in other pain management treatments. * recent injury or surgery: any recent trauma, surgical procedures, or infections in the affected area within the past six months. * medication interference: current or recent use of moderate to strong analgesics (e.g., tramadol, morphine) that could influence pain assessment. * severe health conditions: individuals with significant systemic illnesses (e.g., severe liver or kidney disease), blood clotting disorders, rheumatoid arthritis or epilepsy. * mental health: presence of current psychiatric disorders, cognitive impairments, or inability to comply with the study protocol.

Keywords: myofascial pain dysfunction syndrome magnesium sulphate lidocaine pain electromyography
double-blind study of topical wbi-1001 cream on patients with psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to evaluate primarily the safety and tolerability and secondarily the efficacy of topically applied wbi-1001 cream in patients with mild to moderate psoriasis. double-blind, randomized, placebo controlled study of 36 patients, treated for 28 days plus a 7 day follow-up.in which the patients were divided into six cohorts: cohort 1 at 0.5% qd;cohort 2 at 0.5% bid; cohort 3 at 1.0% qd; cohort 4 at 1.0% bid; cohort 5 at 2.0% qd; cohort 6 at 2.0% bid.efficacy assessed by pga,target lesion assessment and bsa. safety assessed through vital signs, ecg, aes and plasma pk via cmin, cmax,tmax and auco-t.

patients initiated screening within 4 weeks of commencing study treatment. based on progression of the study, at day 0 patients were assigned to one of six treatment cohorts. patients were randomized to treat all areas except the face, scalp, groin and genital areas. patients in cohort 1 were treated on one side with a thin layer of active cream and the other with placebo; in the absence of significant aes by 14 days after the last treatment in the cohort escalation to the next cohort was allowed, and each cohort respectively. during the treatment period patients visited the study centre weekly for safety, tolerability and efficacy assessment. on these study visit days blood draws were done between 7.00 and 10.00am prior to that morning's application of cream. the study enrolled healthy male and female patients aged 18-65 y.o. with clinical diagnosis of stable plaque psoriasis for \>months affecting a maximum of 6% of bsa with a minimum of 0.5% bsa on each side of the body and a minimum of one plaque at least 2x2 cm on each side excluding elbow and knee.

Eligibility criteria:
inclusion criteria: * pga score at day 0 must be 2,3 or 4. * in good overall health. * women of child bearing potential to have negative serum beta-human chorionic gonadotropin pregnancy test before randomization * must be prepared to use adequate means of contraception * must not be lactating. * male partners of females in the study must be prepared to use adequate means of contraception. * must comply with study protocol and attend all visits. * provide written consent prior to participating in the study. exclusion criteria: * spontaneously improving or rapidly deteriorating psoriasis. * patients with other diseases (especially dermatological, immunodeficiency or neurological/psychiatric) that might interfere with assessment of plaque psoriasis. * systemic immunomodulatory therapy in past 36 weeks, phototherapy in past 4 weeks, various psoriatic chemotherapies and beta blockers in the past 2 weeks

Keywords: topical cream application mild to moderate psoriasis
computerized evaluation of the endometrial myometrial junction during a natural menstrual cyle.

Conditions: Infertility

Summary: the investigators aim to evaluate the width of the endometrial myometrial zone in participants during natural menstrual cycle by using specific computerized application on 3 dimensions sonographic images of their uteri.

the uterine endometrium and the uterine myometrium have different acoustic characterization in transvaginal ultrasound(tvs).tvs can also demonstrate the interface between these tissues - the endometrial myometrial zone(emj) .this is optimally achieved in 3 dimensions images in a coronal section of the uterus.a specific computerized algorithm was developed in our unit by using matlab software for the quantitative measurements of the emj width in different uterine planes.the investigators aim to evaluate changes in the width of the emj in different uterine planes in participants during natural menstrual cycle .

Eligibility criteria:
inclusion criteria:patients with regular menstrual cycles - exclusion criteria:patients on contraceptive pills.patients after uterine surgery -
ropivacaine through continuous infusion versus epidural morphine for postoperative analgesia after emergency cesarean section

Conditions: Postoperative Pain

Summary: the cesarean section is one of the most commonly performed surgeries in the world and it represents 20% of the births in france. postoperative pain is moderate-to-severe during the first 48 hours after this procedure. thereby its control is prominent for the medical team in order to shorten the duration of hospital stay as well as to permit an early return to daily activities for these surgical patients. pain control after cesarean section is usually based on non-opioids and epidural administration of morphine if an epidural catheter has been previously placed for the procedure. however epidural morphine is associated with a number of side effects. wound infiltration with local anesthetics has been widely used in the multimodal management of postoperative pain and it may reduce postoperative morphine consumption. in patients enrolled for emergency cesarean delivery with epidural catheter, the objective of this study will be to compare the analgesia provided by a local anesthetic wound 48-hours infusion through a multiorifice catheter (ropivacaine 2 mg/ml) versus epidural analgesia (epidural morphine bolus). quality of pain control will be assessed with the measurements of morphine consumption and pain scores at rest and during mobilisation over 48 hours. at 3 months, patients will be interviewed to assess their residual pain and their satisfaction. it is hypothesized that local anesthetic wound infusion would be non-inferior than epidural morphine analgesia to control pain after cesarean section, and be associated with a reduction of side effects related to the analgesics.


Eligibility criteria:
inclusion criteria: * minimum age 18 years * asa-1 and 2 parturient * emergency cesarean delivery under epidural anesthesia * suprapubic incision used for cesarean section * functional epidural catheter before the cesarean decision (asa scores : physical status score) exclusion criteria: * asa-3 and 4 parturient * bmi \> 35 (before pregnancy) * existing chronic pain * contra-indication to study treatments * chronic use of analgesics or morphinic * preeclampsia * infection * \< 37 weeks pregnant +/- 3 days

Keywords: postoperative pain postoperative morphine consumption emergency cesarean delivery ropivacaine local anesthetic wound 48-hours infusion emergency cesarean section
webmap for childhood cancer survivors

Conditions: Chronic Pain; Survivorship; Childhood Cancer

Summary: background: there are over 500,000 survivors of childhood cancer in north america alone. one in four survivors experiences chronic pain after treatment has completed. youth with chronic pain report increased anxiety, depression, activity limitations, and sleep disturbances. an 8-week web-based cognitive-behavioral treatment for chronic pain (webmap) has demonstrated reduction in the pain in children but has not yet been explored in survivors. the objectives of the current study are to (1) test the feasibility and acceptability of webmap for a sample of survivors with chronic pain and their parents, (2) assess the acceptability of webmap using qualitative interviews, (3) assess webmap's effect on activity limitations, pain intensity, depression and anxiety symptoms, and sleep disturbances, and (4) assess webmap's effect on parent pain catastrophizing and parental response to their child's pain. methods: a single-arm mixed-methods pre-post intervention study design will be utilized. participants will be 34 survivors and at least one of their parents/caregivers. inclusion criteria are (1) cancer history (2) current age 11-17 years, (3) \>2 years post-treatment or \>5 years post-diagnosis, (4) pain present over prior 3 months impairing \>1 area of daily life and occurring \>1/month , (5) computer access with broadband internet. survivors will complete a pre-treatment questionnaire, which will include: child activity limitations interview, the pain intensity numerical rating scale, promis - and pain interference, anxiety, depression, and adolescent sleep wake scale. parents will complete the pain catastrophizing scale - parent version and the adult responses to child symptoms. upon completion of pre-treatment questionnaires (t0), survivors will begin webmap. after the 8 week intervention, survivors will complete the same measures (t1), and at 3 month follow-up (t2). post-treatment interviews will be conducted to determine acceptability. feasibility will be assessed via recruitment and retention rates. treatment engagement will be measured by number of modules completed. pre-post outcome data will be assessed using linear mixed models. qualitative data will be analyzed using thematic analysis. patient and caregiver partners will be involved in study design, recruitment, interpretation of results, and knowledge translation. discussion: investigating whether webmap is useful to survivors will be an important step in improving pain management in this population.


Eligibility criteria:
inclusion criteria: * history of any cancer diagnosis * current age 11-17 years * at least 2 years post-treatment or completed treatment and at least 5 years post-diagnosis * pain present over prior 3 months that impairs at least one area of daily life and occurs at least 1/month * computer access and literacy exclusion criteria: * not able to read/understand english * developmental delays that would prevent them from completing the survey themselves or complete the intervention * psychosis
study response of 13-valent conjugate pneumococcal vaccine in patients with end stage renal disease

Conditions: End Stage Renal Disease

Summary: the purpose of the study is to determine the response of 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis. the study will also try to determine streptococcus pneumoniae colonization in patients 50 years or older with end stage renal disease on dialysis.

the purpose of the study is to determine the immunogenicity of 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis. patients will receive one dose of 0.5ml of prevnar-13 intra-muscularly. antibody response to pneumococcal serotypes will be studied ar 2months and 12 months after administration of vaccine. the study will try to determine streptococcus pneumoniae colonization in patients 50 years or older with end stage renal disease on dialysis and also investigate if there are any change in streptococcus pneumoniae colonization after prevnar-13 vaccination.

Eligibility criteria:
inclusion criteria: * adult patients ≥ 50years of age with end stage renal disease on dialysis (both hemodialysis and peritoneal dialysis). * scheduled to receive pneumococcal vaccine either after 5years of previous vaccination or starting vaccination as part of standard care during the study period exclusion criteria: * history of s. pneumoniae infection within the last 5 years * vaccinated with an influenza- or diphtheria-containing vaccine within the last 6 months * history of any severe adverse reaction associated with a vaccine * received gamma-globulins within the previous 6 months * known or suspected hiv or on immunosuppressive medications. * functional or anatomic asplenia * serious chronic medical condition

Keywords: pneumococcal vaccine end stage renal disease dialysis